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ABSTRACT 
Objective: The objective of the current study was to develop and validate a novel RP-HPLC method for determination of bamifylline hydrochloride 
in pharmaceutical dosage form. 
Methods: Chromatographic separation was conducted on Agilent technologies-1260 series with the G1311C quaternary pump, eclipse XDB C18 
column (4.6 mm i.d. X 250 mm, 5 µm particle sizes) and equipped with photodiode array detector G1315D. Mobile phase consisted of methanol and 
acetonitrile were mixed in the ratio of 90:10 v/v, was used at a flow rate of 1 ml/min and detection wavelength was set at 263 nm. 
Results: The retention time for bamifylline hydrochloride was found to be 2.913 min. The calibration was linear (r2= 0.9996) in the concentration 
range of 2-10 µg/ml. The limit of detection and the limit of quantitation were found to be 0.4825 μg/ml and 1.4621 µg/ml respectively. Recovery of 
bamifylline hydrochloride in tablet formulation was observed in the range of 99.6-99.8 %. Percentage assay of bamifylline hydrochloride (Bamifix) 
was found to be 99.4 % w/w.  
Conclusion: Thus the novel proposed method for bamifylline hydrochloride was found to be feasible for the estimation of bamifylline 
hydrochloride in bulk as well as a pharmaceutical dosage form.  
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The chemical name of bamifylline hydrochloride is 8-Benzyl-7-[2-[N-
ethyl-N-2-hydroxyethyl amino) ethyl] theophylline hydrochloride (fig. 
1). Bamifylline hydrochloride is a theophylline derivative and is used 
as Anti-asthmatic agent [1], bronchodilator [2], a Non-selective 
phosphodiesterase inhibitor and chronic obstructive pulmonary 
disease (COPD). Mechanism of action of bamifylline hydrochloride is 
an adenosine A1 receptor antagonist [3]. Generally, bamifylline 
hydrochloride is not converted to theophylline in the body. Bamifylline 
and theophylline drugs are bronchodilators and their synthetic origin 
and belong to Xanthine. Theophylline and the physical mixtures TA-
NSD [4] and compatibility studies with different polymers [5] were 
investigated by using a polarizing microscope, FTIR, DSC, PXRD and 
KFT. A thorough literature survey of bamifylline hydrochloride 
revealed that very few analytical methods have been reported for 
estimation of bamifylline hydrochloride hitherto. The majority of 
methods for determination of bamifylline hydrochloride in biological 
fluids and pharmaceutical dosage forms include liquid 
chromatography with ultraviolet detection [6] HPLC [7-11], HPTLC 
[12, 13]. This novel proposed method contributes quick estimation, 
correct peak shape, precise, simple, and quick, use of smaller sample 
volumes and utilizing methanol as a mobile phase which is economical 
when compared with other existing methods. So it is necessary to 
develop a simple, precise and rapid RP-HPLC method for quantitative 
determination of bamifylline hydrochloride. This work describes the 
validation parameters stated by the International Conference on 
Harmonization [ICH] guidelines Q2 (R1) [14, 15]. 
 
 
Fig. 1: Chemical structure of bamifylline hydrochloride from 
pubchem 
MATERIALS AND METHODS 
Chemicals and reagents 
The above said the standard drug was gifted from Hetero Labs Ltd., 
Hyderabad, India. All the chemicals used in this method were of 
high-grade purity and purchased from Merck Chemical Division Ltd., 
Mumbai. HPLC grade acetonitrile, water, methanol and 
triethylamine were obtained from Merck Pharmaceuticals private 
Ltd., Mumbai, India. Commercial tablets of the above said 
formulation was obtained from a local pharmacy. 
Instrumentation and conditions  
The high pressure liquid chromatographic system utilized was an 
Agilent high-pressure liquid chromatograph 1260 series with the 
GI311C quaternary pump, eclipse XDB-C18 column (5 µm particle 
size x 4.6 × 250 mm) (made in USA) and a diode array detector 
G1315D was utilized. Ezchrome elite software was used for 
chromatography data acquisition, processing and control of HPLC 
chromatograph. Digital pH meter (systronics model-802), an 
electronic balance (Shimadzu TX223L), a sonicator (spectral lab, 
model UCB 40) and UV-Visible spectrophotometer (systronics 
model-2203) were used in this study. 
Preparation of mobile phase 
To prepare mobile phase HPLC grade methanol and acetonitrile 
were mixed in the ratio of 90:10 % v/v and was filtered through 
0.45 μm nylon membrane filter and degassed by sonication. 
Preparation of stock and working standard solutions 
Accurately 10 mg of pure bamifylline hydrochloride was weighed 
and transferred in 10 ml clean volumetric flask and 5 ml mobile 
phase was added, if necessary sonicate to dissolve. The volume was 
adjusted up to the mark with the mobile phase. This is the primary 
stock solution of bamifylline hydrochloride with a concentration of 
1000 μg/ml. The secondary stock solution is prepared by adding 1 
ml of primary stock solution in 10 ml volumetric flask and made up 
the volume with a mobile phase having the concentration range 100 
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μg/ml. five working standard solutions were prepared for 
calibration graph by adding defined volumes of the secondary stock 
solution and diluting with the mobile phase. The concentrations of 
bamifylline hydrochloride are 2, 4, 6, 8 and 10 µg/ml respectively.  
Sample preparation for tablets 
Accurately weighed twenty bamifylline hydrochloride tablets and 
average weight was calculated. Accurately weighed a portion of tablet, 
powder equivalent to 100 mg of bamifylline hydrochloride and transfer 
into a 100 ml volumetric flask to this 50 ml mobile phase was added and 
sonicated for 15 min. Mobile phase was adjusted up to the mark. The 
solution was filtered using 0.45 µm nylon filter. From the above solution 
pipette out 1.0 ml into a 100 ml volumetric flask and dilute with mobile 
phase up to the mark and mix well. Further diluted to get desired 
concentration. The amount present in the tablet was calculated from 
plotted calibration graph or utilizing regression equation. 
After setting the chromatographic conditions and stabilizing the 
instrument to obtain a steady baseline, the sample solution was 
loaded in the 20 µl fixed sample loop of the injection port. 
Analytical method validation  
Once the chromatographic and the experimental conditions were 
established, the method was validated by the determination of the 
following parameters such as specificity, system suitability, linearity, 
precision, accuracy, robustness, limit of detection (LOD), limit of 
quantitation (LOQ) as per ICH Q2 (R1) guidelines. 
System suitability parameters 
The chromatographic systems used for analysis must pass system 
suitability before going to start the experiment. At first HPLC system 
is stabilized for forty minutes. Inject blank preparation (single 
injection) and standard preparation (six replicates) and record the 
chromatograms to evaluate the system suitability parameters such 
as tailing factor (NMT 1.5), theoretical plate count (NLT 3000) and 
retention time. The % RSD for the peak area of six replicate 
injections of Sofosbuvir standard NMT 2.0. The parameters such as 
tailing factor, % RSD and theoretical plates were studied.  
Linearity 
A standard stock solution of the bamifylline hydrochloride (1 
mg/ml) was prepared with the mobile phase. To study the linearity 
range of drugs, serial dilutions were made from standard stock 
solution in the range of 2-10 µg/ml. 
Specificity 
Specificity of an analytical method is its ability to measure 
accurately and specifically the analyte of interest without 
interference from placebo and degradation products. The specificity 
of the method was established by injecting blank, placebo and 
standard solution in triplicate and recording the chromatograms. 
Precision 
The precision of the method was determined by repeatability 
(intraday) and intermediate precision (interday). Repeatability was 
determined by performing six repeated analysis of the same 
working solution of bamifylline hydrochloride on the same day, 
under the same experimental conditions. The intermediate precision 
of the method was assessed by carrying out the analysis on different 
days and also by another analyst performing the analysis in the 
same laboratory (between-analysts). 
Accuracy 
The accuracy of a method is defined as the closeness of a measured 
value to the true value. The recovery studies were carried out at 50 
%, 100 %, and 150 % of the target level in the tablet in triplicate 
each in the presence of placebo.  
Robustness 
The robustness was determined by analyzing the same sample 
under a variety of conditions. The factors considered to be: 
variations in the flow rate, the organic ratio of mobile phase and pH. 
There were no significant changes in the chromatographic pattern 
when the above modifications were made in the experimental 
conditions, showing thus that the method is robust. The % RSD of 
bamifylline hydrochloride should be not more than 2.0 %. 
LOD and LOQ 
Limit of detection is the lowest concentration in a sample that can be 
detected, but not necessarily quantified under the stated 
experimental conditions. The limit of quantitation is the lowest 
concentration of analyte in a sample which can be quantitatively 
determined with suitable precision and accuracy. LOD and LOQ were 
calculated based on using following formulas, LOD = 3.3 x σ/S and 
LOQ = 10 x σ/S, where σ is the deviation response. S is the slope of 
the calibration curve.  
RESULTS AND DISCUSSION 
Method development and optimization 
The current study was aimed at developing a sensitive, rapid and 
accurate reversed-phase HPLC method for the analysis of 
bamifylline hydrochloride in bulk drug and in pharmaceutical 
dosage form. In order to get decorous retention time, sharp and 
well-resolved peak, the parameters such as different flow rates, 
detection wavelength, a choice of mobile phases containing 
acetonitrile, methanol, and HPLC grade water were studied. Good 
quality symmetrical sharp peak, minimum tailing factor in short 
run time was obtained with C18 column and mobile phase 
composed of methanol: acetonitrile in the ratio of 90:10 v/v, at a 
flow rate of 1 ml/minute with maximum lambda max at 263 nm. 
All the system suitability parameters were computed at the 
optimised chromatographic conditions. The retention time of 
2.913, plate number of 12215 and a tailing factor of 1.112 were 
obtained for bamifylline hydrochloride. The obtained values of the 
entire system suitability parameters are within the limits of the 
agreeable range, which shows that the proposed method is fit for 
detection of bamifylline hydrochloride in the tablet form. The 
optimum chromatographic conditions and system suitability 
parameters are tabulated in table 1. 
 
Table 1: Optimized chromatographic conditions and system suitability parameters 
Parameter Chromatographic conditions 
Instrument Agilent Technologies 1260 series with the G1311C quaternary pump. 
Column Eclipse XDB C18 column (4.6 mm i.d. X 250 mm, 5 µm particle size) 
Detector 1260 series DAD VL photo diode array detector G1315D 
Mobile phase Methanol: acetonitrile (90: 10 % v/v) 
Flow rate 1 ml/minute 
Detection wavelength UV at 263 nm 
Runtime 10 min 
Temperature  Room temperature (25 °C) 
Volume of injection loop 20 µl 
Retention time * 2.913 min 
Theoretical plates [th. pl]*  12215  
Tailing factor*  1.112 
 *= number of six determinations. 
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The calibration curve was constructed between concentrations 
versus peak area by the prepared in the concentration range of 
2-10 µg/ml of stock solution. The linearity range was found to be 
2-10 µg/ml and the results are tabulated in table 2. The 
calibration graph of bamifylline hydrochloride is presented in 
fig. 2. The regression equation was found to be Y = 
60359x+2678.1. The correlation coefficient of bamifylline 
hydrochloride r2 was noted as 0.9996 which states that the 
method was good linear to the concentration versus peak area 
responses. The results show that a phenomenal relationship 
between peak area and concentration of the drug in the 
calibration curve. The standard chromatograms of bamifylline 
hydrochloride are presented in fig. 3 to fig. 7. 
 
Fig. 2: Calibration graph of bamifylline hydrochloride 
 
Table 2: Calibration data of bamifylline hydrochloride 
S. No. Concentration (μg/ml) Peak area, (mAu) 
1 2 121573 
2 4 249585 
3 6 369733 
4 8 480018 
5 10 605006 
 
 
Fig. 3: Standard chromatogram bamifylline hydrochloride (2 µg/ml) 
 
 
Fig. 4: Standard chromatogram bamifylline hydrochloride (4 µg/ml) 
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Fig. 5: Standard chromatogram bamifylline hydrochloride (6 µg/ml) 
 
 
Fig. 6: Standard chromatogram bamifylline hydrochloride (8 µg/ml) 
 
 
Fig. 7: Standard chromatogram bamifylline hydrochloride (10 µg/ml) 
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Commonly used tablet excipients did not interfere with this method. 
It shows that the method is specific. Furthermore, the well-shaped 
peaks also indicate the specificity of the method. The specificity 
results are tabulated in table 3. 
Precision 
System precision is shown in table 4. It was noted that the 
percentage RSD values of precision for Intra-day and inter-day 
(table 5) precision was 0.0008 and 0.0007 respectively. Intra-day 
and inter-day % RSD values lower than 2% clearly assuring that 
this method was found to be fairly precise and reproducible. 
Accuracy 
Regarding accuracy, a known amount of the standard drug was added to 
the fixed amount of preanalyzed sample solution. % recovery was 
calculated by comparing the area before and after addition of the 
standard drug. The standard addition method was performed at 50 %, 
100 % and 150 % levels. The high value of recoveries obtained for 
bamifylline hydrochloride indicates that the proposed method was 
found to be accurate. The recovery results are presented in table 6. 
  
Table 3: Specificity study 
Name of the solution Retention time (tR) min. 
Mobile phase No peaks 
Placebo No peaks 
BMF 10 µg/ml  2.913 min. 
 
Table 4: Results of system precision 
Sample Concentration (µg/ml) Injection no. Peak area (mAU) mean±SD*   % RSD# 









  6 605985 
 *Each value is represented as a mean±SD of 5 observations (n=5), SD: Standard Deviation, RSD: Relative Standard Deviation, #Acceptance criteria<2.0. 
 
Table 5: Intra-day and Inter-day precision data of bamifylline 
Concentration (μg/ml) Intra-day precision Inter-day precision 
Day 1 Day 2 Day 3 
6 369733 369732 369731 369732 
369731 369733 369734 369738 
369737 369734 369727 369726 
369735 369730 369729 369729 
369738 369735 369730 369741 
369730 369738 369736 369735 
mean±SD* 3.224±3697 2.732±3697 3.311±3697 5.612±3697 
 % RSD# 0.000872 0.000739 0.000896 0.001518 
*Each value is represented as a mean±SD of 5 observations (n=5), SD: Standard Deviation, RSD: Relative Standard Deviation, #Acceptance criteria<2.0. 
 
Table 6: Accuracy study 
The amount of the sample 
added (µg/ml) 
The amount of standard drug solution 
added (µg/ml) 





6 3 50 % 99.7 0.11 
6 6 100 % 99.8 0.09 
6 9 150 % 99.6 0.13 
 *Average of triplicate injections 
 
Table 7: Robustness results of bamifylline hydrochloride 
Parameter  Optimized  Used  Retention time (min)  Plate count$  Peak asymmetry # Remark  
 Flow rate 
(±0.2 ml/min)  
1.0 
ml/min  
0.8 ml/min 2.917  12,200 1.190  *Robust  
1.0 ml/min  2.913  12,215 1.25  *Robust  
1.2 ml/min  2.911  12,300  1.21  *Robust  
Detection wavelength 
(±5 nm)  
 263 nm  258 nm  2.912  12,245  1.113 Robust  
263 nm  2.913  12,215  1.112  Robust  
268 nm  2.913  12,225  1.113  Robust  
Mobile phase composition 
(Methanol: Acetonitrile) (±0.5%)  
 90:10 v/v 
 
95:05 v/v  2.911  12,649  1.202  *Robust  
90:10 v/v  2.913  12,215  1.25  *Robust  
85:15 v/v  2.919  12,440  1.102  *Robust  
Acceptance criteria (Limits): #Peak Asymmetry<1.5, $Plate count>2000, * Significant change in Retention time. 
 
Robustness 
The robustness of the developed method was evaluated by small 
deliberate changes in method parameters such as flow rate (±0.2 
ml/min), detection wavelength (±5 nm) and mobile phase composition 
(±0.5 %). The % RSD values of robustness which is less than 2 % reveals 
that the proposed method is robust. The results of robustness study 
results are shown in table 7. Even though the small changes in the 
Ravisankar et al. 
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conditions did not significantly effect on the peak asymmetry, plate 
count and retention time of bamifylline hydrochloride. 
LOD and LOQ 
The developed method found to be high sensitivity with LOD of 
0.4825 μg/ml and LOQ of 1.4621 μg/ml. The LOD and LOQ values 
are presented in table 8. The results of LOD and LOQ supported the 
sensitivity of the developed method. 
Analysis of tablet formulation 
The developed, validated method was successfully applied for the 
determination of bamifylline hydrochloride in their tablet dosage 
form. The assay result (table 9) shows that the amount of the drug 
was in excellent agreement with the labelled value of the 
formulation. The representative sample chromatogram of 
bamifylline hydrochloride is shown in fig. 8. Eventually, summary of 
validation parameters is shown in table 10. 
 
Table 8: LOD and LOQ results of bamifylline hydrochloride 
Limit of Detection (LOD) 0.4825 μg/ml  
Limit of Quantitation (LOQ) 1.5922 μg/ml 
  
Table 9: Results of analysis of bamifylline hydrochloride 
S. No Formulation Labelled amount mg/tablet Amount found mg/tablet Mean % assay±SD % RSD* 
1 Bamifix tablets 600  595.01  99.4±1  0.100 
*Average of six determinations; SD: standard deviation; RSD: relative standard deviation. 
 
 
Fig. 8: Bamifylline hydrochloride sample chromatogram 
 
Table 10: Summary of validation parameters 
 Validation parameters  Results 
Detection wavelength (λmax) 263 nm 
Beer’s law limits (µg/ml) 2–10 µg/ml 
Regression equation Y = 60359x+2678.1 
 Correlation coefficient (r2) 0.9996 
Flow rate 1 ml/minute 
Retention time (Rt) 2.913 min 
Intra-day Precision (% RSD) 0.0008 
Inter-day Precision (% RSD) 0.0007 
Accuracy (% recovery) 99.6-99.8 % w/w 
Limit of Detection (µg/ml) 0.4825 µg/ml 
Limit of Quantitation (µg/ml) 1.4621 µg/ml 
Assay (% w/w) 99.4 % w/w 
 
CONCLUSION 
In conclusion, a simple, accurate, sensitive, rapid and precise RP-
HPLC method was developed and validated for the estimation of 
bamifylline hydrochloride in pharmaceutical dosage form. Statistical 
analysis for the above said results obviously demonstrates that the 
method is fit for the estimation of bamifylline hydrochloride in 
tablet forms without any interference. This method can help 
research studies, quality control and routine analysis with lesser 
resources available. The results of the assay of pharmaceutical 
formulation of the developed method are highly reliable and 
reproducible and is in good agreement with the label claim of the 
drug. Hence the method can be used for the regular analysis of 
bamifylline hydrochloride in tablet dosage form without any 
interference of excipients. 
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